Expression of Concern
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 12, Issue 7 pp 6018—6029

Reversal of multidrug resistance in leukemia cells using a transferrin-modified nanomicelle encapsulating both doxorubicin and psoralen

class="figure-viewer-img"

Figure 3. Cytotoxicity of different combinations of DOX in K562 and K562/DOX cells. (A) The cytotoxicity of both carriers was examined by MTT assays. (B) The antileukemia effect of four formulations of DOX in K562 cells was determined by MTT assays. (C, D) The antileukemia effects of different combinations of DOX in K562/DOX cells was examined by (C) MTT assays and (D) plate cloning experiments. of the effect on apoptosis caused by various delivery systems was examined by (E) flow cytometry and (F) western blot analysis. Data are shown as mean ± standard deviation (n=3), ** P < 0.05.